YISAIPU, an antibody drug independently developed by Sunshine Guojian Pharmaceuticals (Shanghai) Co., Ltd., a subsidiary of 3SBio, has been launched recently in Philippines, reflecting its strong presence in overseas markets. So far, YISAIPU has obtained marketing authorizations in 15 countries, including Colombia, Mexico, India and Thailand.
On the evening of February 20, 2020 local time in the Philippines, the Philippine Rheumatology Association (PRA) Annual Gala Dinner & Local Launch Ceremony of YISAIPU (local trade name: ETVEZA) were held. The launch ceremony was hosted by PRA and co-sponsored by Mega Lifesciences, the Philippines agent of YISAIPU, and Sunshine Guojian, Top rheumatologists from all levels of hospitals in the Philippines attended the ceremony.
Dr. Julie Li-Yu, PRA's current chairman, and Dr. Juan Javier Lichauco, the incoming chairman, led the gathering of nearly 100 experts to witness the launch of YISAIPU on the 100 million-population southeast Asian island nation. At the invitation of PRA, Professor Lin Jin, chairman of Rheumatology Society of Zhejiang Medical Association and director of Rheumatology Immunology Department of The First Affiliated Hospital, Zhejiang University, who was still in the frontline to combat the coronavirus epidemic, delivered a speech via video.
Professor Lin, based on the detailed multi-country clinical data and application experience of YISAIPU, comprehensively elaborated the safety and efficacy of the product in treating rheumatoid arthritis and ankylosing spondylitis. Facts and data have proved that YISAIPU has significant advantages over biologics such as adalimumab and infliximab. The response from the attendees was very positive.
After the speech, Dr. Lichauco, incoming chairman of PRA, made inspiring comments. Starting from his own experience in medication, he spoke highly of the safety and efficacy of YISAIPU, and said that the listing of YISAIPU will activate market competition, greatly improve drug accessibility locally and benefit more patients, thus having great significance.
YISAIPU was listed in 2005 and has benefited hundreds of thousands of patients so far. It has won professional recognition from clinicians and patients. It was included in Class B drugs in China’s National Drug Reimbursement List in 2017. The successful listing of YISAIPU in Philippines once again demonstrates Sunshine Guojian’s concept of "making innovative antibody drugs within reach” in overseas markets, marking a solid step towards Sunshine Guojian’s goal in seeking global business expansion.
About YISAIPU
YISAIPU (Recombinant Human Tumor Necrosis Factor-α Receptor II: IgG-Fc Fusion Protein) is used for the treatment of rheumatoid arthritis, ankylosing spondylitis and psoriasis. It is the first fully human antibody drug listed in China and the first tumor necrosis factor (TNF-α) inhibitor listed in the field of rheumatism in China, which has filled the gap of domestic enterprises in fully human therapeutic antibody drugs. In addition, YISAIPU’s domestic market share has been in a leading position since 2006.
About Sunshine Guojian
Sunshine Guojian was established in 2002 and is one of the first batch of innovative biopharmaceutical companies focusing on antibody drugs in China. It is a domestic pharmaceutical company that has two launched therapeutic antibody drugs, and had emerged as a leader in antibody drug with its capabilities of independent R&D, manufacturing and commercialization in China. Sunshine Guojian orients its R&D efforts primarily towards innovative therapeutic antibody drugs, and provides quality, safe and effective clinical solutions to the therapeutic areas of major diseases such as auto-immune diseases and tumors. Currently, Sunshine Guojian has 15 anti-body drug candidates (including 7 drug candidates in clinical and new drug registration stage and 8 drug candidates in pre-clinical stage) which are under different development stages, targeting tumor, auto-immune diseases and ophthalmological diseases. Most of those drug candidates are Category I biological products for therapeutic use or monoclonal antibodies, 2 of which are in application for launching, and 5 are in clinical stage. Sunshine Guojian may submit applications to both the National Medical Products Administration and the US Food and Drug Administration for some of those drug candidates, or some may be admitted for priority evaluation. Please visit www.ynzqzl.com for additional information.
Cautionary Note and Forward-Looking Statements
This press release contains forward-looking statements, such as those relating to business or products outlook, or Company's intent, plans, beliefs, expectation, or strategies. These forward-looking statements are based on information currently available to the Company and are stated herein on the basis of the outlook at the time of this release. They are based on certain expectations, assumptions and premises, some of which are subjective or beyond our control. These forward-looking statements may prove to be incorrect or may not be realised in future. With respect to any new product or new indication, we cannot guarantee that we will be able to successfully develop or eventually launch and market such product or indication.
Underlying the forward-looking statements is a large number of risks and uncertainties. Further information regarding these risks and uncertainties may be found in our other public disclosure documents.
Any scientific information discussed may be only preliminary and investigative.
Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.